Tesamorelin
Tesamorelin — A synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 44 amino acids with a trans-3-hexenoic acid modification at the N-terminus.
What Is Tesamorelin?
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with an added trans-3-hexenoic acid group at the N-terminus. This modification protects against DPP-IV enzymatic cleavage. Molecular weight: 5135.9 Da.
Mechanism of Action
Tesamorelin binds the GHRH receptor (GHRHR) on anterior pituitary somatotrophs with equivalent affinity to native GHRH. Receptor activation stimulates the Gs/adenylyl cyclase/cAMP/PKA pathway, resulting in growth hormone gene transcription, synthesis, and pulsatile secretion.
Research and Clinical Background
- FDA approval: Tesamorelin (marketed as Egrifta) received FDA approval in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy
- Body composition: Phase III trials demonstrated significant reduction in visceral adipose tissue measured by CT scan
- IGF-1 and GH: Studies confirmed physiological increases in GH pulsatility and IGF-1 levels within the normal range
- Cognitive research: Preliminary studies examined effects on cognitive function in aging populations
Storage
Store lyophilized tesamorelin at -20°C. Due to its large size (44 amino acids), reconstitute slowly with bacteriostatic water and allow several minutes for complete dissolution. Use within 14 days at 2-8°C.
Frequently Asked Questions
What is Tesamorelin?
A synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 44 amino acids with a trans-3-hexenoic acid modification at the N-terminus.
Why is Tesamorelin important in peptide research?
Tesamorelin is a fundamental concept in compound as it relates to peptide science. It directly influences experimental design, compound characterization, and the reliability of research outcomes across biochemistry and molecular biology disciplines.